AJM300 (Carotegrast Methyl), an Oral Antagonist of α4-Integrin, as Induction Therapy for Patients with Moderately Active Ulcerative Colitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Study

溃疡性结肠炎 医学 安慰剂 敌手 双盲 内科学 胃肠病学 替代医学 受体 病理 疾病
作者
Katsuyoshi Matsuoka,Mamoru Watanabe,Toshihide Ohmori,Kouichi Nakajima,Tetsuya Ishida,Yoh Ishiguro,Kazunari Kanke,Kiyonori Kobayashi,Fumihito Hirai,Kenji Watanabe,Hidehiro Mizusawa,Shuji Kishida,Yoshiharu Miura,Akira Ohta,Toshifumi Kajioka,Toshifumi Hibi∥,AJM Study Group
出处
期刊:Social Science Research Network [RELX Group (Netherlands)]
被引量:2
标识
DOI:10.2139/ssrn.3978554
摘要

Background: AJM300 is an oral, small-molecule α4-integrin antagonist. We assessed the efficacy and safety of AJM300 in patients with moderately active ulcerative colitis (UC).Methods: This randomised, double-blind, placebo-controlled study allocated patients 1:1 to receive either AJM300 (960 mg) or placebo with a Mayo Clinic score (MCS) of 6–10, endoscopic subscores (ES) ≥ 2, rectal bleeding subscores (RBS) ≥ 1, and an inadequate response/intolerance to at least 5-aminosalicylic acid (5-ASA). The study drug was administered orally, three times daily for eight weeks, and continued for up to 24 weeks if endoscopic remission or disappearance of rectal bleeding was not achieved. The primary endpoint was clinical response (reduction in MCS of ≥ 30% and ≥ 3 points, reduction in RBS of ≥ 1 point or RBS of ≤ 1, and ES of ≤ 1) at week 8. The efficacy and safety of re-treatment with AJM300 in patients who relapsed after an initial response to AJM300 were also evaluated. Findings: Between June 2018 and May 2021, 203 patients were randomised (102 to AJM300 and 101 to placebo). The proportions of clinical responses at week 8 in the AJM300 and placebo groups were 45·1% and 20·8%, respectively (odd ratio = 3·30, 95% confidence interval, 1·73−6·29) (P = 0·0003). The incidence of adverse events was similar between AJM300 and placebo (38·2% vs 38·6%). Twenty-six patients who relapsed after AJM300 treatment were re-treated with AJM300 , with a clinical response rate of 73·1%. There was no difference in the incidence of adverse events even with repeated administration.Interpretation: AJM300 was well tolerated and effectively induced a clinical response in moderately active UC patients who had an inadequate response or intolerance to at least 5-ASA. Re-treatment with AJM300 may be effective.Funding Statement: This study was funded by EA Pharma Co., Ltd. and Kissei Pharmaceutical Co., Ltd.Clinical Trial Registration Details: Clinicaltrials.gov: NCT03531892.Declaration of Interests: K. Matsuoka has received research support and lecture/consulting fees from AbbVie, EA Pharma, Mitsubishi Tanabe Pharma, Mochida, Kyorin, Kissei, Astellas Pharma, JIMRO, Janssen, Pfizer, Takeda, Zeria, Gilead Sciences, Miyarisan, Nippon Kayaku, Celltrion Healthcare, Eli Lilly; M. Watanabe has received research support and lecture/consulting fees from AbbVie GK., EA Pharma Co., Ltd., Mitsubishi Tanabe Pharma, Mochida, Kyorin, Kissei, JIMRO, Janssen, Pfizer, Takeda, Zeria, Gilead Sciences, Miyarisan, Nippon Kayaku, Celltrion Healthcare, Eli Lilly; T. Ohmori has received research support and lecture/consulting fees from Mochida, Janssen, Mitsubishi Tanabe Pharma, Takeda, Daiichi Sankyo, Otsuka, Olympus Corporation, JIMRO, Kyorin, EA Pharma; K. Nakajima, T. Ishida, Y. Ishiguro, K. Kanke, K. Kobayashi has nothing to disclose; F. Hirai has received research support and lecture/consulting fees from Abbvie, EA Pharma Co, Janssen, Mochida, Mitsubishi Tanabe Pharma, Takeda; K. Watanabe has received research support and lecture/consulting fees from Mitsubishi Tanabe, Takeda, AbbVie, EA Pharma, Kissei, Pfizer, Kyorin, Mochida, Zeria, JIMRO, Otsuka, Asahi Kasei; H. Mizusawa has received research support and lecture/consulting fees from EA Pharma; S. Kishida has received research support and lecture/consulting fees from EA Pharma; Y. Miura has nothing to disclose; A. Ohta and T. Kajioka are employees of EA Pharma; T. Hibi has received research support and lecture/consulting fees from Aspen, EA Pharma, AbbVie, JIMRO, Zeria, Otsuka, Mitsubishi Tanabe Pharma, Kyorin, Janssen, Mochida, Takeda, Gilead Sciences, Celltrion Healthcare, Nippon Kayaku, Kissei, Ferring, Eli Lilly, Pfizer, Nichi-Iko, Nippon Kayaku, Bristol-Myers Squibb.Ethics Approval Statement: All patients gave written informed consent before initiation of any study-specific procedures. The study was conducted in accordance with the ethical principles originating in or derived from the Declaration of Helsinki, and Good Clinical Practice guidelines. The study was designed and conducted by the sponsor in collaboration with the principal investigators. EA Pharma Co., Ltd. monitored study conduct, collected the data, and performed the statistical analyses.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
元吉的应助被子夜歌采纳,获得10
2秒前
虚幻慕凝完成签到,获得积分20
2秒前
张玉燕完成签到,获得积分10
2秒前
4秒前
南瓜饼完成签到,获得积分10
4秒前
Hao发布了新的文献求助10
4秒前
4秒前
7秒前
ccmm完成签到,获得积分10
7秒前
Twinkle发布了新的文献求助10
7秒前
王饼干完成签到,获得积分10
7秒前
陈1完成签到 ,获得积分10
9秒前
9秒前
Orange的应助被星星子采纳,获得10
11秒前
11秒前
大模型的应助被coco采纳,获得10
11秒前
12秒前
12秒前
饱满向梦完成签到 ,获得积分10
12秒前
初景发布了新的文献求助10
13秒前
14秒前
CodeCraft的应助被蔡文圣采纳,获得10
15秒前
15秒前
科研通AI6.2的应助被www采纳,获得10
15秒前
11发布了新的文献求助10
15秒前
大模型的应助被思qi采纳,获得10
16秒前
小杨完成签到,获得积分10
16秒前
无敌咖啡豆完成签到,获得积分10
16秒前
xiaoyu发布了新的文献求助10
18秒前
什玖发布了新的文献求助10
18秒前
18秒前
英俊的铭的应助被碎月采纳,获得10
18秒前
土豆丝关注了科研通微信公众号
19秒前
19秒前
陈1发布了新的文献求助20
19秒前
yangyimin发布了新的文献求助10
20秒前
shenkekeshen的应助被田园采纳,获得10
21秒前
guoan发布了新的文献求助20
22秒前
bunny完成签到 ,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189382
求助须知:如何正确求助?哪些是违规求助? 9576691
关于积分的说明 21849410
捐赠科研通 7787318
什么是DOI,文献DOI怎么找? 3435538
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509